However, the initial choice of long-acting inhaled bronchodilator is not specified ... in preventing COPD exacerbations. In this randomized, controlled, multicenter, international trial, 7376 ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Traditionally, COPD management has relied on bronchodilators ... The other big area of interest is reducing COPD exacerbation frequency. For this, we're studying targeted lung denervation ...

Bronchodilator therapy forms the mainstay of treatment for people with COPD. Bronchodilators work ... of life and reduce the risk of experiencing exacerbations. It is also important to match ...

The use of antibiotics in combination with oral corticosteroids to treat patients with mild-to-moderate exacerbations ... guidelines about bronchodilator use in patients with COPD and CVD are ...

The diagnosis of COPD can be frustrating for both the patient and the physician, especially when a patient is identified as having the frequent-exacerbation phenotype. Counseling these patients is ...

The right treatment plan can help you control your COPD symptoms and avoid exacerbations (flareups). These include shortness ...

Current treatment options for COPD include bronchodilators such as beta2 ... Treatment with Dupixent was shown to reduce COPD exacerbations by 30% in the BOREAS trial and by 34% in the NOTUS ...

1 Looking back, he recognizes there were many missed signs prior to this flare-up, also known as a COPD exacerbation. Flare-ups are characterized ... a LABA (long-acting beta 2-adrenergic agonist) ...

The drug was administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD in the ENHANCE-2 study, cutting the rate of moderate to severe exacerbations ...

Furthermore, an analysis of ensifentrine’s impact on reducing exacerbation rates and COPD-related healthcare resource utilization over 48 weeks will also be presented. “Ensifentrine is a ...